An analysis of the EudraVigilance database examined 31,444 total adverse event reports for semaglutide, liraglutide, and tirzepatide combined
Retatrutides Phase 2 results landed on the cover of the New England Journal of Medicine in 2023, before Phase 3 even finished
Personalized Peptide Protocol Development for Your Goals 5
Clinical Trial Insights In a Phase 2 clinical trial published in The New England Journal of Medicine , Retatrutide demonstrated remarkable efficacy: Participants with obesity (without diabetes) experienced up to 24.2% reduction in body weight over 48 weeks, surpassing results seen with existing medications
Cut sugars and processed carbs (usually the #1 most important thing) to stabilize insulin and curb hunger and cravings
Armand Ntchana, who was awarded the Family Medicine Cares Resident Service Award to conduct this program in Rapides parish